Corcept Therapeutics CORT Long-term accrued government rebates
Long-term accrued government rebates at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept cort:LongTermAccruedGovernmentRebates.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's long-term accrued government rebates.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Corcept Therapeutics's long-term accrued government rebates?
- Corcept Therapeutics (CORT) reported long-term accrued government rebates of $4.37M in Q1 2026.
- What does long-term accrued government rebates mean?
- Long-term financial obligations for government-mandated drug rebates.
- How do you interpret long-term accrued government rebates?
- An increase may reflect higher sales volume in government-reimbursed channels or changes in regulatory rebate requirements.
- How does long-term accrued government rebates compare across companies?
- Specific to the pharmaceutical industry; peers with similar product portfolios will have comparable rebate structures.